Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 AM PT (1:30 PM EST) on Wednesday, January 15, 2025. Live audio of the event can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
新澤西州帕西帕尼，2025年1月2日（環球新聞通訊社）—— Pacira BioSciences（納斯達克：PCRX）今天宣佈，將於2025年1月15日（星期三）上午10:30（太平洋時間）在第43屆摩根大通醫療會議上進行演講。通過訪問公司網站投資者頁面（investor.pacira.com）的「活動」頁面，可以收聽活動的實時音頻。活動後的兩週內也將提供網絡直播的回放。
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioverao, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit .
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioverao, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit .
CONTACT: Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com
聯繫方式：公司聯繫人：
Pacira BioSciences, Inc.
克里斯蒂安·佩德蒂
(973) 254-4387
Christian.pedetti@pacira.com
譯文內容由第三人軟體翻譯。
